NEW YORK (GenomeWeb News) — Illumina has licensed Oxford Gene Technology patents that will enable Illumina to detect DNA sequence variations, OGT said today.
Under the deal, OGT has granted Illumina access to the property through the life of the patents and provides “certain rights with respect to SNP genotyping,” OGT said.
Illumina CEO Jay Flatley said the licensing agreement is “relevant to a portion of our products and will not materially impact our expected financial results."
Financial terms of the deal were not released.
The news comes one month after Illumina said it plans to acquire next-generation DNA-sequencing technology company Solexa for around $600 million in stock.